⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL670662 | 0.91 | — | — | |
| SCHEMBL16498878 | 0.90 | — | — | |
| SCHEMBL16991930 | 0.86 | — | — | |
| SCHEMBL194317 | 0.69 | THRB (0.30) | — | |
| SCHEMBL9277463 | 0.69 | — | — | |
| SCHEMBL16432080 | 0.68 | — | — | |
| SCHEMBL27880841 | 0.67 | — | — | |
| SCHEMBL18398447 | 0.67 | — | — | |
| SCHEMBL2750776 | 0.67 | — | — | |
| SCHEMBL698563 | 0.66 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 255 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12224439-B2 | Boron-containing chemicals as cathode additives, Si anode additives, electrolyte additives or separator modifiers for Li-ion batteries | ENEVATE CORPORATION (US) | 2025-02-11 | — | — | US | claimed |
| WO-2022093717-A1 | BORON-CONTAINING CHEMICALS AS CATHODE ADDITIVES, SI ANODE ADDITIVES, ELECTROLYTE ADDITIVES OR SEPARATOR MODIFIERS FOR LI-ION BATTERIES | ENEVATE CORPORATION (US) | 2022-05-05 | — | — | WO | claimed |
| US-20220131148-A1 | BORON-CONTAINING CHEMICALS AS CATHODE ADDITIVES, SI ANODE ADDITIVES, ELECTROLYTE ADDITIVES OR SEPARATOR MODIFIERS FOR LI-ION BATTERIES | ENEVATE CORPORATION | 2022-04-28 | — | — | US | claimed |
| US-20200388885-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH LIPO2F2 SALT-CONTAINING ELECTROLYTE FORMULATIONS | ENEVATE CORPORATION | 2020-12-10 | — | — | US | claimed |
| US-12630566-B2 | KRas G12D inhibitors | Mirati Therapeutics, Inc. (US) | 2026-05-19 | — | — | US | disclosed |
| US-12617802-B2 | Sulfonimidamide compounds as NLRP3 modulators | GENENTECH, INC. (US) | 2026-05-05 | — | — | US | disclosed |
| EP-4582428-A1 | PYRAZOLOPYRIMIDINE COMPOUND AND PHARMACEUTICAL USE THEREOF | Japan Tobacco Inc. (JP) | 2025-07-09 | — | — | EP | disclosed |
| US-12344597-B2 | Alkoxy-substituted pyridinyl derivatives as LPA1 receptor antagonists and their use in the treatment of fibrosis | IDORSIA PHARMACEUTICALS LTD (CH) | 2025-07-01 | — | — | US | disclosed |
| US-20250114361-A1 | PYRAZOLOPYRIMIDINE COMPOUND AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2025-04-10 | — | — | US | disclosed |
| WO-2025036241-A1 | COMPOUNDS AND METHODS FOR MODULATING RNA SPLICING | RIBOPEUTIC INC. (CN) | 2025-02-20 | — | — | WO | disclosed |
| US-12224439-B2 | Boron-containing chemicals as cathode additives, Si anode additives, electrolyte additives or separator modifiers for Li-ion batteries | ENEVATE CORPORATION (US) | 2025-02-11 | — | — | US | disclosed |
| CN-119330941-A | Antitumor compounds as UPR agonists and uses thereof | 南京圣和药业股份有限公司 | 2025-01-21 | — | — | CN | disclosed |
| US-7122627-B2 | Lactam inhibitors of Hepatitis C virus NS3 protease | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-10-17 | — | — | US | disclosed |
| US-20040171556-A1 | Methods for inhibiting proteasome | BRISTOL-MYERS SQUIBB COMPANY | 2004-09-02 | — | — | US | disclosed |
| WO-2004064755-A2 | METHODS FOR INHIBITING PROTEASOME | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-08-05 | — | — | WO | disclosed |
| US-20030008828-A1 | Diagnostic kits; for therapy of viral infection; as assat standard or reagent | BRISTOL-MYERS SQUIBB COMPANY | 2003-01-09 | — | — | US | disclosed |
| EP-1206449-A1 | LACTAM INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-05-22 | — | — | EP | disclosed |
| EP-1196436-A2 | PEPTIDE BORONIC ACID INHIBITORS OF HEPATITIS C VIRUS PROTEASE | Bristol-Myers Squibb Pharma Company (US) | 2002-04-17 | — | — | EP | disclosed |
| WO-2001007407-A1 | LACTAM INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-02-01 | — | — | WO | disclosed |
| WO-2001002424-A2 | PEPTIDE BORONIC ACID INHIBITORS OF HEPATITIS C VIRUS PROTEASE | DU PONT PHARMACEUTICALS COMPANY (US) | 2001-01-11 | — | — | WO | disclosed |